185 related articles for article (PubMed ID: 33025213)
1. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO).
Sepúlveda-Sánchez JM; Gil-Gil M; Alonso-García M; Vaz Salgado MÁ; Vicente E; Mesía Barroso C; Rodríguez Sánchez Á; Durán G; De Las Peñas R; Muñoz-Langa J; Velasco G; Hernández-Laín A; Hilario A; Navarro Martín M; Benavides M; Oleaga L; Cantero Montenegro D; Ruano Y; Sánchez-Gómez P; Martín-Soberón MC; Morales-Llombart R; Pachón V; Pineda E
Target Oncol; 2020 Oct; 15(5):613-622. PubMed ID: 33025213
[TBL] [Abstract][Full Text] [Related]
2. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
3. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao L; Dai J; Cao Y; Bai X; Sheng X; Chi Z; Cui C; Kong Y; Zhang Y; Wu L; Wang X; Tang B; Lian B; Yan X; Li S; Zhou L; Wei X; Li C; Qi Z; Si L; Guo J
Eur J Cancer; 2021 May; 148():297-306. PubMed ID: 33770575
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.
Guo L; Hu Y; Chen X; Li Q; Wei B; Ma X
Cancer Med; 2019 Apr; 8(4):1389-1400. PubMed ID: 30897298
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
Vaughn DJ; Hwang WT; Lal P; Rosen MA; Gallagher M; O'Dwyer PJ
Cancer; 2015 May; 121(9):1463-8. PubMed ID: 25522918
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
10. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
11. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M
J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
13. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
[TBL] [Abstract][Full Text] [Related]
14. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
16. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract][Full Text] [Related]
17. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
18. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Van Mater D; Gururangan S; Becher O; Campagne O; Leary S; Phillips JJ; Huang J; Lin T; Poussaint TY; Goldman S; Baxter P; Dhall G; Robinson G; DeWire-Schottmiller M; Hwang EI; Stewart CF; Onar-Thomas A; Dunkel IJ; Fouladi M
Pediatr Blood Cancer; 2021 Apr; 68(4):e28879. PubMed ID: 33405376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
